Citations

Showing 10 of 108104 citations.

Faculty Opinions recommendation of Continuous renal replacement therapy versus intermittent hemodialysis as first modality for renal replacement therapy in severe acute kidney injury: a secondary analysis of AKIKI and IDEAL-ICU studies.
Kashani, Kianoush

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 28, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.742016734.793592702 Get It

Overexpression of the energy metabolism transcriptome within clonal plasma cells is associated with the pathogenesis and outcomes of patients with multiple myeloma
Evans, Laura A. , Anderson, Emilie A., Jessen, Erik , Nandakumar, Bharat , Atilgan, Ezgi, Hitosugi, Taro , Kumar, Shaji , Gonsalves, Wilson I. , Kumar, Shaji K , Gonsalves, Wilson , Anderson, Emilie I., Jevremović, Dragan , Fonseca, Rafaël

Mayo Clinic

American Journal of Hematology | April 28, 2022 | Volume: 97 | Issue: 7 | Pages: 895-902

10.1002/ajh.26577 | PMID 35481878 Get It

AbstractAltered energy metabolism and changes in glycolytic and oxidative phosphorylation pathways are hallmarks of all cancer cells. The expression of select genes associated with the production of various enzymes and proteins involved in glycolysis and oxidative phosphorylation were assessed in the clonal plasma cells derived from patients with newly diagnosed multiple myeloma (NDMM) enrolled in the Multiple Myeloma Research Foundation (MMRF) CoMMpass data set. A scoring system consisting of assigning a point for every gene where their fragments per kilobase of transcript per million (FPKM) was above the median yielded a minimum of 0 and a maximum of 12 for the set of genes in the glycolytic and oxidative phosphorylation pathways to create a total energy metabolism molecular signature (EMMS) score. This EMMS score was independently associated with worse progression free survival (PFS) and overall survival (OS) outcomes of patients with NDMM. A higher EMMS score was more likely to be present in clonal plasma cells derived from Multiple myeloma (MM) patients than those from patients with monoclonal gammopathy of undetermined significance (MGUS). This was functionally confirmed by the clonal plasma cells from MM patients having a higher rate of mitochondrial and glycolysis‐derived ATP formation than clonal plasma cells from MGUS patients. Thus, this study provides evidence for the effect of energy metabolism within clonal plasma cells on pathogenesis and outcomes of patients with MM. Exploiting the energy‐producing metabolic pathways within clonal plasma cells for diagnostic and therapeutic purposes in MM should be explored in the future.
An in vitro model for Extracellular DNA Traps (ETs)-rich Human Thrombus Analogs
Liu, Yang , Dai, Daying , Abbasi, Mehdi , Mereuta, Oana Madalina , Gamb, Scott I., Kadirvel, Ramanathan , Kallmes, David F. , Brinjikji, Waleed , Dai, Daying , Madalina Mereuta, Oana , Liu, Yang

Mayo Clinic

Journal of NeuroInterventional Surgery | April 28, 2022 | Volume: 15 | Issue: 6 | Pages: 589-593

10.1136/neurintsurg-2022-018790 | PMID 35483911 Get It

Background Extracellular DNA traps (ETs) have important implications in both thrombosis and thrombolysis. Thus, developing benchtop thrombus analogs that recapitulate clinical ETs is potentially of great value for preclinical development and testing of thrombolytic agents and thrombectomy devices. In this study, we aimed to develop ETs-rich thrombus analogs for preclinical testing. Methods Red blood cell (RBC)-rich, fibrin-rich, and platelet-rich thrombus analogs were created using human whole blood, platelet-poor plasma, and platelet-rich plasma obtained from the blood bank following institutional approval. Peripheral blood mononuclear cells (9.9×106 cells/mL) isolated from human whole blood and lipopolysaccharide (1 µg/mL) were added to induce ETs. Histochemical, immunohistochemistry and immunofluorescence were used to identify thrombus components and ETs. Scanning electronic microscopy was used to investigate the ultrastructure of the thrombus analogs. The thrombus compositions, morphologic features of ETs and citrullinated histone H3 (H3Cit) expression were compared with those of thrombi retrieved from patients by thrombectomy. Results ETs-rich thrombus analogs were more compacted th-an the ETs-poor thrombus analogs. ETs were identified in both ETs-rich thrombus analogs and patient thrombi showing morphologic features including nuclear lobulation, nuclear swelling, diffused chromatin within cytoplasm, DNA/chromatin extending intracellularly and extracellularly, and extracellular chromatin patches and bundles. In the ETs-poor thrombus analogs, ETs were not observed and H3Cit expression was absent to minimal. The compositions and H3Cit expression in the ETs-rich thrombus analogs fell in the range of patient thrombi. Conclusions ETs-rich thrombus analogs can be consistently created in vitro and may benefit the preclinical development and testing of new thrombolytic agents and thrombectomy devices.
Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation
Porrata, Luis F. , Inwards, David J. , Ansell, Stephen M. , Micallef, Ivana N. , Johnston, Patrick B. , Paludo, Jonas , Villasboas, José C. , Paludo, Jonas , Markovic, Svetomir N.

Mayo Clinic

Leukemia & Lymphoma | April 28, 2022 | Volume: 63 | Issue: 10 | Pages: 2436-2443

10.1080/10428194.2022.2064988 | PMID 35481444 Get It

Letter: The Morbidity and Mortality of Surgery for Traumatic Brain Injury in Geriatric Patients: A Study of Over 100 000 Patient Cases
Kerezoudis, Panagiotis , Puffer, Ross C. , Parney, Ian F.

Mayo Clinic

Neurosurgery | April 28, 2022 | Volume: 91 | Issue: 1 | Pages: e20-e21

10.1227/neu.0000000000002008 | PMID 35482321 Get It

High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition
Adams, Anngela C. , Borden, Elizabeth S. , Macy, Anne M. , Thomson, Nick, Cui, Haiyan , Gimbel, Mark, Wilson, Melissa A. , Buetow, Kenneth H. , Roe, Denise J. , DiCaudo, David J. , Homsi, Jade , Hastings, Karen Taraszka , Hastings, K Taraszka , Buetow, Kenneth

Mayo Clinic

Cancers | April 28, 2022 | Volume: 14 | Issue: 9 | Pages: 2200

10.3390/cancers14092200 | PMID 35565329 Get It

Gamma-interferon-inducible lysosomal thiol reductase (GILT) is critical for MHC class II restricted presentation of multiple melanoma antigens. There is variable GILT protein expression in malignant melanocytes in melanoma specimens. High GILT mRNA expression in melanoma specimens is associated with improved overall survival, before the advent of immune checkpoint inhibitors (ICI). However, the association of GILT in metastatic melanoma with survival in patients treated with ICI and the cell type expressing GILT associated with survival have not been determined. Using RNA sequencing datasets, high GILT mRNA expression in metastatic melanoma specimens was associated with improved progression-free and overall survival in patients treated with ICI. A clinical dataset of metastatic melanoma specimens was generated and annotated with clinical information. Positive GILT immunohistochemical staining in antigen presenting cells and melanoma cells was observed in 100% and 65% of metastatic melanoma specimens, respectively. In the subset of patients treated with ICI in the clinical dataset, high GILT protein expression within melanoma cells was associated with improved overall survival. The association of GILT mRNA and protein expression with survival was independent of cancer stage. These studies support that high GILT mRNA expression in bulk tumor samples and high GILT protein expression in melanoma cells is associated with improved survival in ICI-treated patients. These findings support further investigation of GILT as a biomarker to predict the response to ICI.
Selecting venues for AMIA events and conferences: guiding ethical principles
Lehmann, Christoph U. , Hollis, Kate Fultz , Petersen, Carolyn , DeMuro, Paul R. , Subbian, Vignesh , Koppel, Ross , Solomonides, Anthony , Pan, Eric, Fultz Hollis, Kate , Solomonides, Anthony E , Pan, Eric C , Goodman, Kenneth W , Koppel, Ross , Lehmann, Christoph U , Petersen, Carolyn , Subbian, Vignesh , Berner, Eta S. , Adler‐Milstein, Julia , Goodman, Kenneth W.

Mayo Clinic

Journal of the American Medical Informatics Association | April 28, 2022 | Volume: 29 | Issue: 8 | Pages: 1319-1322

10.1093/jamia/ocac073 | PMID 35579334 Get It

Abstract A discussion and debate on the American Medical Informatics Association’s (AMIA) Ethical, Legal, and Social Issues (ELSI) Working Group listserv in 2021 raised important issues related to a forthcoming conference in Texas. Texas had recently enacted a restrictive abortion law and restricted voting rights. Several AMIA members advocated for a boycott of the state and the scheduled conference. The discussion led the AMIA Board of Directors to request that the organization’s Ethics Committee provide general guidance for principle-based venue selection. This document recommends overarching principles for the venue selection for future AMIA events and conferences. Discussions by the AMIA Board, the Ethics Committee, and the ELSI Working Group informed these recommendations, and this document on guiding principles was approved by the AMIA Board of Directors in April 2022.
Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain
BouSaba, Joelle, Sannaa, Wassel , Camilleri, Michael

Mayo Clinic

Therapeutic Advances in Gastroenterology | April 28, 2022 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/17562848221078638 | PMID 35509419 Get It

Chronic noncancer pain (CNCP) affects up to 20% of adults and can interfere with activities of daily living. Up to 4% of adults in the United States receive chronic opioid therapy and up to 57% of patients on long-term opioids for CNCP report opioid-induced constipation (OIC). OIC is essentially constipation occurring after starting opioid treatment. While laxatives are traditionally the first-line therapy for OIC, 81% of patients taking daily laxatives and opioids still reported OIC and considered that it negatively affected their quality of life. Naldemedine is a peripherally acting µ-opioid receptor antagonists (PAMORA) approved for the treatment of OIC in patients with CNCP. This article reviews the mechanism of action, efficacy, and safety of naldemedine in CNCP patients. Naldemedine improves OIC in patients with CNCP by acting as an opioid receptor antagonist in the gastrointestinal tract. It does not interfere with the analgesic properties of opioids or cause withdrawal symptoms since these effects are centrally mediated, and naldemedine does not cross the blood brain barrier. Naldemedine showed significant and sustained improvement in frequency of bowel movements, quality of life, and constipation-related symptoms. It is generally well tolerated with a higher incidence of gastrointestinal adverse events of mild or moderate severity such as diarrhea, abdominal pain, or vomiting compared to placebo. While there are no randomized, controlled trials that compare head-to-head pharmacological therapies used for treatment of OIC, network meta-analysis shows that naldemedine has an overall good benefit-risk profile compared to the other approved medications.
Application of an F0-based genetic assay in adult zebrafish to identify modifier genes of an inherited cardiomyopathy
Wang, Mingmin , Li, Jiarong , Xu, Xiaolei , Ding, Yonghe , Wang, Mingmin , Bu, Haisong, Lin, Xueying , Bu, Haisong

Mayo Clinic

Disease Models & Mechanisms | April 28, 2022 | Volume: 16 | Issue: 5 | Pages: No page available

10.1242/dmm.049427 | PMID 35481478 Get It

ABSTRACT Modifier genes contribute significantly to our understanding of pathophysiology in human diseases; however, effective approaches to identify modifier genes are still lacking. Here, we aim to develop a rapid F0-based genetic assay in adult zebrafish using the bag3 gene knockout (bag3e2/e2) cardiomyopathy model as a paradigm. First, by utilizing a classic genetic breeding approach, we identified dnajb6b as a deleterious modifier gene for bag3 cardiomyopathy. Next, we established an F0-based genetic assay in adult zebrafish through injection of predicted microhomology-mediated end joining (MMEJ)-inducing single guide RNA/Cas9 protein complex. We showed that effective gene knockdown is maintained in F0 adult fish, enabling recapitulation of both salutary modifying effects of the mtor haploinsufficiency and deleterious modifying effects of the dnajb6b gene on bag3 cardiomyopathy. We finally deployed the F0-based genetic assay to screen differentially expressed genes in the bag3 cardiomyopathy model. As a result, myh9b was identified as a novel modifier gene for bag3 cardiomyopathy. Together, these data prove the feasibility of an F0 adult zebrafish-based genetic assay that can be effectively used to discover modifier genes for inherited cardiomyopathy.